Celera Genomics said Immunex had purchased 5-year subscriptions to several of its genomic databases.
Details of the transaction were not disclosed, but earlier subscribers to Celera’s databases have reportedly paid between $25 million and $50 million for three- to five-year periods.
Based in Seattle, Immunex markets the arthritis drug Enbrel.